A study of physico-chemical interactions between Haemophilus influenzae type b and meningococcus group C conjugate vaccines.
نویسندگان
چکیده
BACKGROUND Haemophilus influenzae type b (Hib) and Meningococcal group C (MenC) conjugate vaccines, which protect against otitis media, bacteremia and invasive diseases, including pneumonia and meningitis, are attractive candidates for combination, since they are both administered to infants and children. A Hib-MenC combination booster at 12 mo has recently been introduced in the U.K. OBJECTIVES To rule out the possibility for the individual vaccine components in a Hib-MenC combination to interact, rendering one or both of them less effective, this work assessed whether these two saccharide-protein conjugates, namely, Hib oligosaccharide-CRM(197) (Cross-Reacting Material 197) and MenC-CRM(197), interact in solution. Furthermore an evaluation of the size and integrity of the vaccines was also performed. METHODS HPLC Size-exclusion chromatography (SEC) with UV-adsorption and refractive index detection was performed with a phosphate and non-phosphate saline buffer to characterize the size of Hib and MenC conjugates as individual components or when combined. RESULTS Hib-CRM(197) eluted significantly earlier than MenC-CRM(197) in both phosphate-saline and MOPS-saline buffers on a TSK5000 PWXL column. When combined, there was no significant change in their elution. Refractive index monitoring showed no evidence of significant free saccharide or free protein. CONCLUSIONS By size-exclusion chromatography and refractive index detection methods, there was no indication of degradation, and no evidence of significant associative interactions between Hib-CRM(197) and MenC-CRM(197) in saline-based buffers, pH 7.2.
منابع مشابه
Immunogenicity and Efficacy of Different Haemophilus influenzae type b Vaccines
Haemophilus influenzae, a major cause of meningitis in young children leading to death and other neurological sequelae. The disease leaves 15 to 35% of the survivors with permanent disabilities, such as, mental retardation or deafness. Despite the availability of new and more powerful antibiotics children with Hib meningitis still suffer from high mortality or morbidity. The emergence of multir...
متن کاملImprovement of Large-scale PRP production by Haemophilus influenzae typeb, using modified CY medium
Background and Objective: Haemophilus influenzae type b (Hib) is a gram negative bacterium and one of the most common causative agents of acute meningitis in infants and less than 5 years old children worldwide. The production of Hib capsular polysaccharide polyribosyl ribitolphosphate (PRP) is important for the production of conjugate vaccines against Hib infections. The aim of this study is t...
متن کاملExtraction and Purification of Haemophilus influenzae Type b Lipooligosaccharide by Modified Phenol Method
Introduction : Haemophilus influenzae type b (Hib) is a Gram negative bacterium and one of the causative agents of acute bacterial meningitis, especially in infants and children less than 5 years old. Lipooligosaccharide (LOS), one of the virulence factors which plays an important role in pathogenesis of Hib, has multiple applications in diagnosis and conjugate vaccines. In this study, LOS ex...
متن کاملImmune competence after alemtuzumab treatment of multiple sclerosis.
OBJECTIVE To determine the immunocompetency of patients with multiple sclerosis treated with the lymphodepleting humanized monoclonal antibody alemtuzumab. METHODS In this pilot case-control study, we assessed immunocompetence in 24 patients after alemtuzumab treatment by measuring antibody responses to 3 vaccines (diphtheria, tetanus, and poliomyelitis vaccine, Haemophilus influenzae type b ...
متن کاملSafety and immunogenicity of two Haemophilus influenzae type b conjugate vaccines.
OBJECTIVES Haemophilus influenzae type b (Hib) infection remains a major public health problem in the developing world. We evaluated the safety and immunogenicity of a new PRP-CRM197 conjugate Hib vaccine (Vaxem Hib, Chiron Vaccines), compared with the HibTITER vaccine (Wyeth-Lederle Vaccines), following the World Health Organisation (WHO)'s accelerated schedule which allows 4-week intervals be...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- African health sciences
دوره 7 4 شماره
صفحات -
تاریخ انتشار 2007